These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 8523052)

  • 1. Phase II trial of docetaxel in patients with advanced cutaneous malignant melanoma previously untreated with chemotherapy.
    Bedikian AY; Weiss GR; Legha SS; Burris HA; Eckardt JR; Jenkins J; Eton O; Buzaid AC; Smetzer L; Von Hoff DD
    J Clin Oncol; 1995 Dec; 13(12):2895-9. PubMed ID: 8523052
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase II trial of docetaxel (Taxotere) in patients with metastatic melanoma previously untreated with cytotoxic chemotherapy.
    Einzig AI; Schuchter LM; Recio A; Coatsworth S; Rodriquez R; Wiernik PH
    Med Oncol; 1996 Jun; 13(2):111-7. PubMed ID: 9013474
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II and pharmacologic study of docetaxel as initial chemotherapy for metastatic breast cancer.
    Hudis CA; Seidman AD; Crown JP; Balmaceda C; Freilich R; Gilewski TA; Hakes TB; Currie V; Lebwohl DE; Baselga J; Raptis G; Gollub M; Robles M; Bruno R; Norton L
    J Clin Oncol; 1996 Jan; 14(1):58-65. PubMed ID: 8558221
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II trial of docetaxel: a new, highly effective antineoplastic agent in the management of patients with anthracycline-resistant metastatic breast cancer.
    Valero V; Holmes FA; Walters RS; Theriault RL; Esparza L; Fraschini G; Fonseca GA; Bellet RE; Buzdar AU; Hortobagyi GN
    J Clin Oncol; 1995 Dec; 13(12):2886-94. PubMed ID: 8523051
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II trial of docetaxel in patients with advanced or metastatic transitional-cell carcinoma.
    McCaffrey JA; Hilton S; Mazumdar M; Sadan S; Kelly WK; Scher HI; Bajorin DF
    J Clin Oncol; 1997 May; 15(5):1853-7. PubMed ID: 9164195
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I trial of docetaxel administered as a 1-hour infusion in children with refractory solid tumors: a collaborative pediatric branch, National Cancer Institute and Children's Cancer Group trial.
    Blaney SM; Seibel NL; O'Brien M; Reaman GH; Berg SL; Adamson PC; Poplack DG; Krailo MD; Mosher R; Balis FM
    J Clin Oncol; 1997 Apr; 15(4):1538-43. PubMed ID: 9193350
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Corticosteroids significantly delay the onset of docetaxel-induced fluid retention: final results of a randomized study of the European Organization for Research and Treatment of Cancer Investigational Drug Branch for Breast Cancer.
    Piccart MJ; Klijn J; Paridaens R; Nooij M; Mauriac L; Coleman R; Bontenbal M; Awada A; Selleslags J; Van Vreckem A; Van Glabbeke M
    J Clin Oncol; 1997 Sep; 15(9):3149-55. PubMed ID: 9294478
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Docetaxel: an active drug for squamous cell carcinoma of the head and neck.
    Dreyfuss AI; Clark JR; Norris CM; Rossi RM; Lucarini JW; Busse PM; Poulin MD; Thornhill L; Costello R; Posner MR
    J Clin Oncol; 1996 May; 14(5):1672-8. PubMed ID: 8622087
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Docetaxel in patients with metastatic breast cancer: a phase II study of the National Cancer Institute of Canada-Clinical Trials Group.
    Trudeau ME; Eisenhauer EA; Higgins BP; Letendre F; Lofters WS; Norris BD; Vandenberg TA; Delorme F; Muldal AM
    J Clin Oncol; 1996 Feb; 14(2):422-8. PubMed ID: 8636752
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II trial of docetaxel in patients with stage III and IV non-small-cell lung cancer.
    Francis PA; Rigas JR; Kris MG; Pisters KM; Orazem JP; Woolley KJ; Heelan RT
    J Clin Oncol; 1994 Jun; 12(6):1232-7. PubMed ID: 7911159
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II trial of docetaxel in patients with platinum-refractory advanced ovarian cancer.
    Francis P; Schneider J; Hann L; Balmaceda C; Barakat R; Phillips M; Hakes T
    J Clin Oncol; 1994 Nov; 12(11):2301-8. PubMed ID: 7964944
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II study of docetaxel for advanced or metastatic platinum-refractory non-small-cell lung cancer.
    Fossella FV; Lee JS; Shin DM; Calayag M; Huber M; Perez-Soler R; Murphy WK; Lippman S; Benner S; Glisson B
    J Clin Oncol; 1995 Mar; 13(3):645-51. PubMed ID: 7884425
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II trial of docetaxel in advanced anthracycline-resistant or anthracenedione-resistant breast cancer.
    Ravdin PM; Burris HA; Cook G; Eisenberg P; Kane M; Bierman WA; Mortimer J; Genevois E; Bellet RE
    J Clin Oncol; 1995 Dec; 13(12):2879-85. PubMed ID: 8523050
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer.
    Chan S; Friedrichs K; Noel D; Pintér T; Van Belle S; Vorobiof D; Duarte R; Gil Gil M; Bodrogi I; Murray E; Yelle L; von Minckwitz G; Korec S; Simmonds P; Buzzi F; González Mancha R; Richardson G; Walpole E; Ronzoni M; Murawsky M; Alakl M; Riva A; Crown J;
    J Clin Oncol; 1999 Aug; 17(8):2341-54. PubMed ID: 10561296
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Temozolomide in combination with docetaxel in patients with advanced melanoma: a phase II study of the Hellenic Cooperative Oncology Group.
    Bafaloukos D; Gogas H; Georgoulias V; Briassoulis E; Fountzilas G; Samantas E; Kalofonos Ch; Skarlos D; Karabelis A; Kosmidis P
    J Clin Oncol; 2002 Jan; 20(2):420-5. PubMed ID: 11786569
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II trial of docetaxel (Taxotere) in patients with adenocarcinoma of the upper gastrointestinal tract previously untreated with cytotoxic chemotherapy: the Eastern Cooperative Oncology Group (ECOG) results of protocol E1293.
    Einzig AI; Neuberg D; Remick SC; Karp DD; O'Dwyer PJ; Stewart JA; Benson AB
    Med Oncol; 1996 Jun; 13(2):87-93. PubMed ID: 9013471
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Docetaxel vs doxorubicin in metastatic breast cancer resistant to alkylating chemotherapy.
    Chan S
    Oncology (Williston Park); 1997 Aug; 11(8 Suppl 8):19-24. PubMed ID: 9364537
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase II study of docetaxel in patients with paclitaxel-resistant metastatic breast cancer.
    Valero V; Jones SE; Von Hoff DD; Booser DJ; Mennel RG; Ravdin PM; Holmes FA; Rahman Z; Schottstaedt MW; Erban JK; Esparza-Guerra L; Earhart RH; Hortobagyi GN; Burris HA
    J Clin Oncol; 1998 Oct; 16(10):3362-8. PubMed ID: 9779713
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II study of docetaxel for recurrent or metastatic non-small-cell lung cancer.
    Fossella FV; Lee JS; Murphy WK; Lippman SM; Calayag M; Pang A; Chasen M; Shin DM; Glisson B; Benner S
    J Clin Oncol; 1994 Jun; 12(6):1238-44. PubMed ID: 7911160
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Docetaxel is a major cytotoxic drug for the treatment of advanced breast cancer: a phase II trial of the Clinical Screening Cooperative Group of the European Organization for Research and Treatment of Cancer.
    Chevallier B; Fumoleau P; Kerbrat P; Dieras V; Roche H; Krakowski I; Azli N; Bayssas M; Lentz MA; Van Glabbeke M
    J Clin Oncol; 1995 Feb; 13(2):314-22. PubMed ID: 7844592
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.